Unique ID issued by UMIN | UMIN000008817 |
---|---|
Receipt number | R000010364 |
Scientific Title | A Study on the efficacy of neoadjuvant chemotherapy with carboplatin, docetaxel and bevacizumab in patients with non-squamous non-small cell lung cancer |
Date of disclosure of the study information | 2012/09/01 |
Last modified on | 2014/09/10 17:04:52 |
A Study on the efficacy of neoadjuvant chemotherapy with carboplatin, docetaxel and bevacizumab in patients with non-squamous non-small cell lung cancer
A Study on the efficacy of neoadjuvant chemotherapy with carboplatin, docetaxel and bevacizumab in patients with non-squamous non-small cell lung cancer
A Study on the efficacy of neoadjuvant chemotherapy with carboplatin, docetaxel and bevacizumab in patients with non-squamous non-small cell lung cancer
A Study on the efficacy of neoadjuvant chemotherapy with carboplatin, docetaxel and bevacizumab in patients with non-squamous non-small cell lung cancer
Japan |
Non-Squamous Non-Small Cell Lung Cancer
Pneumology | Chest surgery |
Malignancy
NO
To evaluate the efficacy and safety of neoadjuvant chemotherapy with carboplatin, docetaxel and bevacizumab in patients with non-squamous non-small cell lung cancer
Safety,Efficacy
Exploratory
Pragmatic
Pathological complete resection rate
Pathological response rate (pRR)
Complete resection rate
Relapse-free survival (RFS)
Overall survival (OS)
Safety
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine | Maneuver |
Carboplatin + Docetaxel + Bevacizumab
day1 q3w 2cycles
Surgical operation is performed over 5 weeks after protocol therapy.
20 | years-old | <= |
75 | years-old | > |
Male and Female
1) Histologically or pathologically confirmed non-squamous non-small cell lung cancer
2) Clinical stage IB- IIIA
3) Age:20-74years old
4) ECOG PS 0-1
5) Patients without previous treatment for lung cancer
6) If the patient underwent therapy, there should be the following interval between the therapy and the registration
-Open biopsy,Treatment of injury->2 weeks
-Aspiration biopsy,->1 week
7) Sufficient organ function
8) Written IC
1) History of severe drug allergy
2) Patients with uncontrollable complications
3) Patients with symptomatic Brain metastasis
4) History of hemoptysis ( >= 2.5mL)
5) History of continuous hemosputum
6) Patients with massive pleural and cardiac effusion
7) Patients with uncontrollable peptic ulcer
8) History of myocardial infarction or cerebral infarction
9) Current or previous history of GI perforation
10) Patients with therapeutic anticoagulopathy
11) Pregnancy, breast feeding and suspected pregnancy
12) Active concomitant malignancy
13) Inappropriate patients for this study judged by the physicians
28
1st name | |
Middle name | |
Last name | Motohiko Furuichi |
Nihon University School of Medicine Itabashi Hospital
Department of respiratory surgery
30-1 Ohyaguchi kami-machi, Itabashi-ku, Tokyo
03-3972-8111
furuichi.motohiko@nihon-u.ac.jp
1st name | |
Middle name | |
Last name | Motohiko Furuichi |
Nihon University School of Medicine Itabashi Hospital
Department of respiratory surgery
30-1 Ohyaguchi kami-machi, Itabashi-ku, Tokyo
03-3972-8111
furuichi.motohiko@nihon-u.ac.jp
Nihon University School of Medicine Itabashi Hospital
Nihon University School of Medicine Itabashi Hospital
Self funding
Kawaguchi Municipal Medical Center
NO
2012 | Year | 09 | Month | 01 | Day |
Unpublished
Enrolling by invitation
2012 | Year | 02 | Month | 28 | Day |
2012 | Year | 06 | Month | 01 | Day |
2012 | Year | 08 | Month | 31 | Day |
2014 | Year | 09 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000010364